All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
CAT | Product Name | Target Species | Antibody Clone | Antibody Host | Receptor Construction | Vector Type | Targeting Cell Type | CAR Vector Type | Inquiry & Datasheet |
CAR-0320ZP267 | Anti-ASAP1 (7B12) h(CD28-CD3ζ) CAR, pCDCAR1 | Human | 7B12 | Mouse | scFv-CD28-CD3ζ | Lentiviral vector | T Cell | ||
CAR-0320ZP268 | Anti-ASAP1 (7B12) h(4-1BB-CD3ζ) CAR, pCDCAR1 | Human | 7B12 | Mouse | scFv-4-1BB-CD3ζ | Lentiviral vector | T Cell | ||
CAR-0320ZP269 | Anti-ASAP1 (4E8) h(CD28-CD3ζ) CAR, pCDCAR1 | Human | 4E8 | Mouse | scFv-CD28-CD3ζ | Lentiviral vector | T Cell | ||
CAR-0320ZP270 | Anti-ASAP1 (4E8) h(4-1BB-CD3ζ) CAR, pCDCAR1 | Human | 4E8 | Mouse | scFv-4-1BB-CD3ζ | Lentiviral vector | T Cell | ||
CAR-0320ZP271 | Anti-ASAP1 (CBYC-A806) h(CD28-CD3ζ) CAR, pCDCAR1 | Human | CBYC-A806 | Mouse | scFv-CD28-CD3ζ | Lentiviral vector | T Cell | ||
CAR-0320ZP272 | Anti-ASAP1 (CBYC-A806) h(4-1BB-CD3ζ) CAR, pCDCAR1 | Human | CBYC-A806 | Mouse | scFv-4-1BB-CD3ζ | Lentiviral vector | T Cell | ||
CAR-0320ZP273 | Anti-ASAP1 (2G7) h(CD28-CD3ζ) CAR, pCDCAR1 | Human | 2G7 | Mouse | scFv-CD28-CD3ζ | Lentiviral vector | T Cell | ||
CAR-0320ZP274 | Anti-ASAP1 (2G7) h(4-1BB-CD3ζ) CAR, pCDCAR1 | Human | 2G7 | Mouse | scFv-4-1BB-CD3ζ | Lentiviral vector | T Cell | ||
CAR-0320ZP275 | Anti-ASAP1 (1B5) h(CD28-CD3ζ) CAR, pCDCAR1 | Human | 1B5 | Mouse | scFv-CD28-CD3ζ | Lentiviral vector | T Cell | ||
CAR-0320ZP276 | Anti-ASAP1 (1B5) h(4-1BB-CD3ζ) CAR, pCDCAR1 | Human | 1B5 | Mouse | scFv-4-1BB-CD3ζ | Lentiviral vector | T Cell |
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTERCellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTIONSilence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGYCanine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION